Provided by Tiger Trade Technology Pte. Ltd.

Jazz Pharmaceuticals PLC

251.65
+7.112.91%
Volume:479.42K
Turnover:119.13M
Market Cap:16.34B
PE:17.20
High:252.17
Open:244.78
Low:241.39
Close:244.54
52wk High:266.38
52wk Low:123.88
Shares:64.91M
Float Shares:62.69M
Volume Ratio:0.44
T/O Rate:0.76%
Dividend:- -
Dividend Rate:- -
EPS(TTM):14.63
EPS(LYR):-5.8403
ROE:22.11%
ROA:6.86%
PB:3.40
PE(LYR):-43.09

Loading ...

Abcellera Biologics - Jazz Has Exclusive Option to Develop and Commercialize Antibodies From Collaboration

THOMSON REUTERS
·
Jun 17

Jazz announces eleven presentations at SLEEP 2026

TIPRANKS
·
Jun 17

BRIEF-Jazz Pharmaceuticals Delivers Extensive Late-Breaking Data At Sleep 2026, Demonstrating Real-World Impact Of Xywav

Reuters
·
Jun 17

Jazz Pharma says Phase 4 XYLO study shows cardiometabolic risk markers improve after switch to low-sodium Xywav

Reuters
·
Jun 17

Jazz Pharmaceuticals Delivers Extensive Late-Breaking Data at Sleep 2026, Demonstrating Real-World Impact of Xywav® (Calcium, Magnesium, Potassium, and Sodium Oxybates) on Patient Outcomes Across Narcolepsy and Idiopathic Hypersomnia

THOMSON REUTERS
·
Jun 17

Piper Sandler Reaffirms Their Buy Rating on Jazz Pharmaceuticals (JAZZ)

TIPRANKS
·
Jun 16

How Investors Are Reacting To Jazz (JAZZ) Zepzelca Failing Phase 3 LAGOON Survival Endpoint

Simply Wall St.
·
Jun 16

Analysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (JAZZ) and Dianthus Therapeutics (DNTH)

TIPRANKS
·
Jun 15

Jazz Pharma EVP, Chief Legal Officer Neena Patil disposes of 1,200 shares worth $278,196

Reuters
·
Jun 13

Analysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (JAZZ) and Edwards Lifesciences (EW)

TIPRANKS
·
Jun 12

Jazz Pharma's Zepzelca Misses Primary Endpoint in Second-Line Lung-Cancer Trial

Dow Jones
·
Jun 12

Jazz Pharmaceuticals Shares Fall 1.7% Premarket After Co's Lung Cancer Drug Fails Late-Stage Trial

THOMSON REUTERS
·
Jun 12

Jazz Pharmaceuticals says Phase 3 LAGOON trial did not meet primary endpoint

TIPRANKS
·
Jun 12

BRIEF-Jazz Pharmaceuticals Provides Update On Zepzelca Phase 3 Trial

Reuters
·
Jun 12

Jazz Pharma's lung cancer drug fails late-stage trial

Reuters
·
Jun 12

Jazz Pharma says Zepzelca Phase 3 LAGOON trial misses overall survival endpoint in second-line SCLC

Reuters
·
Jun 12

Jazz Pharmaceuticals - Lagoon Trial Results Do Not Impact 2026 Guidance

THOMSON REUTERS
·
Jun 12

Jazz Pharmaceuticals - No New Safety Signals Identified for Zepzelca in Lagoon Trial

THOMSON REUTERS
·
Jun 12

Jazz Pharmaceuticals Provides Update on Zepzelca® (Lurbinectedin) Phase 3 Lagoon Trial in Second-Line Small Cell Lung Cancer

THOMSON REUTERS
·
Jun 12

Jazz Pharmaceuticals - Phase 3 Lagoon Trial of Zepzelca in Second-Line Sclc Does Not Meet Primary Endpoint

THOMSON REUTERS
·
Jun 12